Alkem Laboratories Ltd - 539523 - Disclosure under SEBI (PIT) Reg 2015
Alkem Laboratories Ltd has submitted to BSE a copy of Disclosures under Regulations 4(1) of SEBI (Prohibition of Insider Trading) Regulations, 201522-06-2021
22-06-2021
Alkem Laboratories Ltd - 539523 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Kumar Singh & Aniruddha Singh22-06-2021
Alkem Laboratories Ltd - 539523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Annual Secretarial Compliance Report for the period ended 31st March, 2021 issued by Practising Company Secretary. Kindly take the same on record.21-06-2021
Alkem Laboratories gets two observations from USFDA for St Louis-based formulation plant
The US Food and Drug Administration (USFDA) had conducted an inspection of the company's manufacturing plant at St Louis, USA from June 14-18, 2021.19-06-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted an inspection of the Company's manufacturing facility located at St. Louis, USA from 14th June, 2021 to 18th June, 2021. At the end of the inspection, the Company has received Form 483 with two (2) observations. The Company shall submit to US FDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection. Kindly take the same on record.19-06-2021
Alkem Laboratories Ltd - 539523 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Kumar Singh & Aniruddha Singh11-06-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
This is to intimate you that Alkem Laboratories Limited (the 'Company') has launched Perampanel Tablets in India under the brand name 'Perampil', an affordable anti-epileptic drug for the treatment of Epilepsy in India. Perampanel has received authorization from the Drug Controller General of India (DCGI). A press release in this regard is enclosed herewith. Kindly take the same on record.10-06-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to intimate you that Alkem Laboratories Limited (the 'Company') has launched Perampanel Tablets in India under the brand name 'Perampil', an affordable anti-epileptic drug for the treatment of Epilepsy in India. Perampanel has received authorization from the Drug Controller General of India (DCGI). A press release in this regard is enclosed herewith. Kindly take the same on record.10-06-2021
Alkem Laboratories Ltd - 539523 - Disclosure Of Related Party Transactions On A Consolidated Basis Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosures of related party transactions, on a consolidated basis, for the half year ended on 31st March, 2021 in the prescribed format. The same have been published on the website of the Company at www.alkemlabs.com. Kindly take the same on record.09-06-2021
Buy Alkem; target of Rs 3730: Motilal Oswal
Motilal Oswal is bullish on Alkem recommended buy rating on the stock with a target price of Rs 3730 in its research report dated Jun 07, 2021.09-06-2021